Generon (shanghai) Corporation Ltd.

Itabmed (hk) Limited

Generon Corporation Ltd.

Zhihua Huang

Xiaoqiang Yan

Yuliang Huang

Hongzhou Yang

Yumin Cui

Bill N C Sun

Heng Liu

Xinfeng Zhang

Dongdong Wu

Hanyang Chen

Dong-Dong Wu

Bo Qi

Wuzhong Shen

Yiqun Rao

Bill NC Sun

The present invention provides bispecific antigen binding proteins (BSAPs) that specifically bind to CD3 and a tumor antigen (e.g., CD19). The present invention also provides uses of the BSAPs for the preparation of pharmaceutical compositions, methods of treating cancer, and kits comprising the BSAPs.

Anti-CD19 and anti-CD3 bispecific antigen binding proteins and uses thereof

The present invention provides multispecific Fab fusion proteins (MSFP) that specifically bind to CD3 and EpCAM. The present invention further provides uses of the MSFPs for the preparation of pharmaceutical compositions, methods of treating cancer, and kits comprising the MSFPs. Also provided are anti-EpCAM antibodies or antigen-binding fragments thereof.

Multispecific fab fusion proteins and use thereof

The invention discloses the use of the G-CSF dimer in the preparation of a medicament for the treatment of neurodegenerative diseases. Use of the G-CSF dimer of the present invention can significantly increase the number of dopaminergic neuron in the substantia nigra in PD model animals and enhance the function of dopaminergic neurons. In addition, the G-CSF dimer can significantly reduce apoptosis of neuron in hippocampus and improve learning and memory ability of AD model rats. Serum half-life of the G-CSF dimer of the invention is prolonged and the loss of neurons is effectively prevented, providing a better therapeutic effect in treatment of neurodegenerative disease.

Use of G-CSF dimer in preparation of medicament for treatment of neurodegenerative diseases

This invention relates to a use of IL-22 in the treatment of viral hepatitis. As illustrated in the examples of this invention, IL-22 can significantly reduce liver damage caused by hepatitis virus, and can significantly reduce the increase of transaminase ALT/AST induced by heptatitis virus. In addition, the IL-22 dimer of this invention can effectively treat viral hepatitis.

Use of interleukin-22 in treating viral hepatitis

This invention discloses the uses of IL-22 in the treatment and prevention of a nerve damage disease or a neurodegenerative disease. In particular, the invention discloses the uses of IL-22 or IL-22 dimers as follows: (i) can protect neurons to recover the functions of injured neurons after ischemic nerve damage in animals in vivo, thus enabling effective treatment of nerve damage diseases, (ii) can significantly inhibit the loss of dopaminergic neurons in substantia nigra in PD model animal, enhance the functions of dopaminergic neurons, significantly reduce neuronal apoptosis in hippocampus, improve learning and memory capacity of AD model rats, and effectively prevent neuronal loss, thereby enabling more effective treatment of neurodegenerative diseases.

Uses of interleukin-22(IL-22) in treating and preventing nerve damage diseases or neurodegenerative diseases

This invention relates to a recombinant human G-CSF (rhG-CSF) dimer and its use in the treatment of neurological disorder. In particular, upon ischemic neural injury in animal, this invention can be used to protect neurons with the use of rhG-CSF dimer such that function of injured nerves can be restored. Serum half-life of G-CSF dimer of this invention is prolonged and the biological activity thereof is increased.

Recombinant human G-CSF dimer and use thereof for the treatment of neurological diseases

This invention relates to a use of IL-22 in the treatment of viral hepatitis. As illustrated in the examples of this invention, IL-22 can significantly reduce liver damage caused by hepatitis virus, and can significantly reduce the increase of transaminase ALT/AST induced by hepatitis virus. In addition, the IL-22 dimer of this invention can effectively treat viral hepatitis.

Growing community of inventors

Shanghai, China

Zhihua Huang